EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

Biochemical and Biophysical Research Communications

Volumn 463, Issue 1-2, 2015, Pages 95-101

  Lin, Kailong ^a   Cheng, Jianan ^a   Yang, Tao ^a   Li, Yongsheng ^a   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

EGFR TKI; NF B; NSCLC; PD L1

Indexed keywords

GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE NUCLEIC ACID; PROGRAMMED DEATH 1 LIGAND 1; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RELA PROTEIN, HUMAN; RNA; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT TANDEM REPEAT; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MUTATION; NUDE MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84935004492     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.05.030     Document Type: Article

References (23)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010, CA Cancer J. Clin. 60 (2010) 277-300.
2. K. Florian, H. Wolfgang, S. Andreas, P. Andreas, S. Thomas, G. Richard, A. Jutta, N.S. Meinhard, S. William, T. Alexandar, J. Herbert, K. Karin, Z. August, F. Josef, O. Wilhelm, F. Michael, Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry, Lung Cancer 87 (2015) 193-200.
3. M.D. Fisher, A. D'Orazio, Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594), Clin. Lung Cancer 2 (2000) 21-22.
4. L.V. Sequist, R.G. Martins, D. Spigel, S.M. Grunberg, A. Spira, P.A. Janne, V.A. Joshi, D. McCollum, T.L. Evans, A. Muzikansky, G.L. Kuhlmann, M. Han, J.S. Goldberg, J. Settleman, A.J. Iafrate, J.A. Engelman, D.A. Haber, B.E. Johnson, T.J. Lynch, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, J. Clin. Oncol. 26 (2008) 2442-2449.
5. T.F. Gajewski, Y. Meng, H. Harlin, Immune suppression in the tumor microenvironment, J. Immunother. 29 (2006) 233-240.
6. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, P.D. Leming, D.R. Spigel, S.J. Antonia, L. Horn, C.G. Drake, D.M. Pardoll, L. Chen, W.H. Sharfman, R.A. Anders, J.M. Taube, T.L. McMiller, H. Xu, A.J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G.D. Kollia, A. Gupta, J.M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med. 366 (2012) 2443-2454.
7. E.J. Lipson, C.G. Drake, Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma, Clin. Cancer Res. 17 (2011) 6958-6962.
8. E.A. Akbay, S. Koyama, J. Carretero, A. Altabef, J.H. Tchaicha, C.L. Christensen, O.R. Mikse, A.D. Cherniack, E.M. Beauchamp, T.J. Pugh, M.D. Wilkerson, P.E. Fecci, M. Butaney, J.B. Reibel, M. Soucheray, T.J. Cohoon, P.A. Janne, M. Meyerson, D.N. Hayes, G.I. Shapiro, T. Shimamura, L.M. Sholl, S.J. Rodig, G.J. Freeman, P.S. Hammerman, G. Dranoff, K.K. Wong, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, Cancer Discov. 3 (2013) 1355-1363.
9. H.S. Huang, M. Nagane, C.K. Klingbeil, H. Lin, R. Nishikawa, X.D. Ji, C.M. Huang, G.N. Gill, H.S. Wiley, W.K. Cavenee, The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling, J. Biological Chem. 272 (1997) 2927-2935.
10. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J.M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M.A. Moreno, J. Terrasa, J. Munoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier, J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J.L. Ramirez, J.J. Sanchez, M.A. Molina, M. Taron, L. Paz-Ares, G.F. Pneumocancerologie, A.I.O. Toracica, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. 13 (2012) 239-246.
11. N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G.D. Kao, A. Maity, EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms, Cancer Res. 66 (2006) 3197-3204.
12. S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B.E. Johnson, P.A. Janne, Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255, Cancer Res. 64 (2004) 7241-7244.
13. K. Hotta, K. Kiura, H. Ueoka, M. Tabata, K. Fujiwara, T. Kozuki, T. Okada, A. Hisamoto, M. Tanimoto, Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer, Lung Cancer 46 (2004) 255-261.
14. G. Huang, Q. Wen, Y. Zhao, Q. Gao, Y. Bai, NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment, PLoS One 8 (2013) e61602.
15. K. Tanaka, I. Babic, D. Nathanson, D. Akhavan, D. Guo, B. Gini, J. Dang, S. Zhu, H. Yang, J. De Jesus, A.N. Amzajerdi, Y. Zhang, C.C. Dibble, H. Dan, A. Rinkenbaugh, W.H. Yong, H.V. Vinters, J.F. Gera, W.K. Cavenee, T.F. Cloughesy, B.D. Manning, A.S. Baldwin, P.S. Mischel, Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance, Cancer Discov. 1 (2011) 524-538.
16. S.J. Lee, B.C. Jang, S.W. Lee, Y.I. Yang, S.I. Suh, Y.M. Park, S. Oh, J.G. Shin, S. Yao, L. Chen, I.H. Choi, Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274), FEBS Lett. 580 (2006) 755-762.
17. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, V.A. Lennon, E. Celis, L. Chen, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med. 8 (2002) 793-800.
18. D.L. Barber, E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, G.J. Freeman, R. Ahmed, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature 439 (2006) 682-687.
19. K.A. Schalper, V. Velcheti, D.E. Carvajal-Hausdorf, V. Anagnostou, K. Syrigos, S. Gettinger, L. Chen, R. Herbst, D.L. Rimm, Tumor infiltrating lymphocytes are associated with epithelial expression of PD-L1 protein, PD-L1 mRNA and better outcome in non-small cell lung cancer, Mod. Pathol. 27 (2014) 493a-494a.
20. K. Azuma, K. Ota, A. Kawahara, S. Hattori, E. Iwama, T. Harada, K. Matsumoto, K. Takayama, S. Takamori, M. Kage, T. Hoshino, Y. Nakanishi, I. Okamoto, Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer, Ann. Oncol. 25 (2014) 1935-1940.
21. A. D'Incecco, M. Andreozzi, V. Ludovini, E. Rossi, A. Capodanno, L. Landi, C. Tibaldi, G. Minuti, J. Salvini, E. Coppi, A. Chella, G. Fontanini, M.E. Filice, L. Tornillo, R.M. Incensati, S. Sani, L. Crino, L. Terracciano, F. Cappuzzo, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br. J. Cancer 112 (2015) 95-102.
22. S.X. Jiang, K. Yamashita, M. Yamamoto, C.J. Piao, A. Umezawa, M. Saegusa, T. Yoshida, M. Katagiri, N. Masuda, K. Hayakawa, I. Okayasu, EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance, Int. J. Cancer 123 (2008) 2480-2486.
23. M. Garofalo, G. Romano, G. Di Leva, G. Nuovo, Y.J. Jeon, A. Ngankeu, J. Sun, F. Lovat, H. Alder, G. Condorelli, J.A. Engelman, M. Ono, J.K. Rho, L. Cascione, S. Volinia, K.P. Nephew, C.M. Croce, EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers, Nat. Med. 18 (2012) 74-82.